Abzyme can develop both modular and traditional antibodies with desired attributes to your target antigen.
Camelid VHH antibodies are ideal modular antibodies for the generation of novel biologics with multiple advantages. Abzyme can develop your VHH therapeutic by immunizing llamas, followed by accelerated antibody maturation in yeast.
Our antibody discovery platforms also include human antibody development to your antigen using our large human donor library. Our engineered yeast strains contain multiple attributes that are designed to mimic host affinity maturation for development of tight binding therapeutic candidates.
Abzyme will partner with your company to discover and/or optimize antibodies according to your needs. Each project will result in a panel of candidate antibodies for further development. Projects will have an agreed-upon schedule for milestones, delivery of characterization data and final product. Standard characterization of your antibody panel will include data from surface plasmon resonance, ELISA, flow cytometry, immunohistochemistry and Western blotting.
Our selection process will ensure that candidate antibodies have high affinity, high expression and high manufacturability. The final product can be supplied in various stages of preparation from supernatant to purified IgG.
Llama pre-immunized Yeast Libraries
To accelerate antibody discovery, Abzyme has the following llama pre-immunized yeast libraries, ready to be screened for the following antigens of interest:
|Checkpoint||Blood Cancer||Solid Cancer||Cytokines/GF||Others|
|CTLA-4/CD152||CD19||human HER2||TNF alpha||CD16a|
|OX40/CD134||CD70||FGF2 or bFGF|
|B7-H4 (B7x or B7S1)||CD70||CCL20|